Koru Life Science develops treatments for rare and hard-to-treat diseases by repurposing existing medicines and pairing each one with a clearly defined group of patients.
We work where the need is sharpest — conditions with few or no effective treatments and small, often overlooked patient populations. For these diseases, the conventional model of discovering a new molecule from scratch is usually too slow and too costly. Starting from medicines with established human data changes that equation.
We search approved, clinical-stage and shelved compounds for new therapeutic uses, combining computational evidence with laboratory validation.
Learn more →We identify the biological markers that predict response, so each programme is designed around the patients most likely to benefit.
Learn more →We choose diseases where patients have few or no options and the biology gives a clear point of attack.
We screen existing compounds computationally and experimentally against that biology.
We tie each candidate to a measurable marker that tells us which patients to treat.
We work with academic, clinical, industry and patient partners to move programmes towards the clinic.
Accurate, cautious and transparent in our research and in how we communicate it.
Every programme starts with a patient group that needs a better option.
We can't do it all ourselves, so we build partnerships that make the whole stronger.
Small and focused, so decisions take days rather than months.
Biology is hard. We test our hypotheses rigorously and let the evidence lead.
The UK has deep expertise in genomic medicine, the foundation of patient stratification.
World-class universities and clinical research networks to validate and test ideas.
Active patient organisations and a national rare-disease strategy to work alongside.
We partner across Europe, North America and Asia to take programmes forward.
Three programmes in DIPG, FTD-GRN and advanced chondrosarcoma.